| Catherine Tung Harris, MD | |
|
2700 Clay Edwards Dr Ste 240, North Kansas City, MO 64116-3254 | |
| (816) 691-2021 | |
| (816) 346-7690 |
| Full Name | Catherine Tung Harris |
|---|---|
| Gender | Female |
| Speciality | Hospitalist |
| Experience | 14 Years |
| Location | 2700 Clay Edwards Dr Ste 240, North Kansas City, Missouri |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760794861 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 2013030078 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| North Kansas City Hospital | North kansas city, MO | Hospital |
| St Lukes Hospital Of Kansas City | Kansas city, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Saint Lukes Physician Group Inc | 3577476894 | 1070 |
| Meritas Health Corporation | 6305748153 | 365 |
News Archive
Hyperion Therapeutics, Inc. announced today that its investigational compound glycerol phenylbutyrate (HPN-100) has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) as adjunctive therapy for the chronic management of urea cycle disorders. Hyperion recently completed its phase III trial which was conducted under a Special Protocol Assessment (SPA) agreement with the FDA. The Company plans to announce results from that trial later this year.
A team of researchers have found that the American workplace is a significant contributor to the obesity epidemic. In the review of shifts in the labor force since 1960 it was suggested that a sizable portion of the national weight gain can be explained by declining physical activity during the workday.
Patients with high cholesterol levels who continually take statins appear to have a lower risk of death over four to five years, regardless of whether they already have diagnosed heart disease, according to a report in the February 9 issue of Archives of Internal Medicine , one of the JAMA/Archives journals.
Advanced Cell Technology, Inc. has reported for the first time a robust and highly efficient process for the generation of high-purity hepatocytes (liver cells).
Stem Cell Assurance, Inc. announced today that the Company will be focusing on four business development initiatives Lipo Rejuvenation Centers, Cellular Treatment Programs, Laboratory Science Investigations, and its Skincare Brand, Stem Cellutrition.
› Verified 4 days ago
| Entity Name | Saint Lukes Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093263717 PECOS PAC ID: 3577476894 Enrollment ID: O20031111000818 |
News Archive
Hyperion Therapeutics, Inc. announced today that its investigational compound glycerol phenylbutyrate (HPN-100) has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) as adjunctive therapy for the chronic management of urea cycle disorders. Hyperion recently completed its phase III trial which was conducted under a Special Protocol Assessment (SPA) agreement with the FDA. The Company plans to announce results from that trial later this year.
A team of researchers have found that the American workplace is a significant contributor to the obesity epidemic. In the review of shifts in the labor force since 1960 it was suggested that a sizable portion of the national weight gain can be explained by declining physical activity during the workday.
Patients with high cholesterol levels who continually take statins appear to have a lower risk of death over four to five years, regardless of whether they already have diagnosed heart disease, according to a report in the February 9 issue of Archives of Internal Medicine , one of the JAMA/Archives journals.
Advanced Cell Technology, Inc. has reported for the first time a robust and highly efficient process for the generation of high-purity hepatocytes (liver cells).
Stem Cell Assurance, Inc. announced today that the Company will be focusing on four business development initiatives Lipo Rejuvenation Centers, Cellular Treatment Programs, Laboratory Science Investigations, and its Skincare Brand, Stem Cellutrition.
› Verified 4 days ago
| Entity Name | Meritas Health Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801875091 PECOS PAC ID: 6305748153 Enrollment ID: O20040122001058 |
News Archive
Hyperion Therapeutics, Inc. announced today that its investigational compound glycerol phenylbutyrate (HPN-100) has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) as adjunctive therapy for the chronic management of urea cycle disorders. Hyperion recently completed its phase III trial which was conducted under a Special Protocol Assessment (SPA) agreement with the FDA. The Company plans to announce results from that trial later this year.
A team of researchers have found that the American workplace is a significant contributor to the obesity epidemic. In the review of shifts in the labor force since 1960 it was suggested that a sizable portion of the national weight gain can be explained by declining physical activity during the workday.
Patients with high cholesterol levels who continually take statins appear to have a lower risk of death over four to five years, regardless of whether they already have diagnosed heart disease, according to a report in the February 9 issue of Archives of Internal Medicine , one of the JAMA/Archives journals.
Advanced Cell Technology, Inc. has reported for the first time a robust and highly efficient process for the generation of high-purity hepatocytes (liver cells).
Stem Cell Assurance, Inc. announced today that the Company will be focusing on four business development initiatives Lipo Rejuvenation Centers, Cellular Treatment Programs, Laboratory Science Investigations, and its Skincare Brand, Stem Cellutrition.
› Verified 4 days ago
| Entity Name | Saint Lukes Hospital Of Chillicothe |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245433127 PECOS PAC ID: 0143130393 Enrollment ID: O20041014000548 |
News Archive
Hyperion Therapeutics, Inc. announced today that its investigational compound glycerol phenylbutyrate (HPN-100) has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) as adjunctive therapy for the chronic management of urea cycle disorders. Hyperion recently completed its phase III trial which was conducted under a Special Protocol Assessment (SPA) agreement with the FDA. The Company plans to announce results from that trial later this year.
A team of researchers have found that the American workplace is a significant contributor to the obesity epidemic. In the review of shifts in the labor force since 1960 it was suggested that a sizable portion of the national weight gain can be explained by declining physical activity during the workday.
Patients with high cholesterol levels who continually take statins appear to have a lower risk of death over four to five years, regardless of whether they already have diagnosed heart disease, according to a report in the February 9 issue of Archives of Internal Medicine , one of the JAMA/Archives journals.
Advanced Cell Technology, Inc. has reported for the first time a robust and highly efficient process for the generation of high-purity hepatocytes (liver cells).
Stem Cell Assurance, Inc. announced today that the Company will be focusing on four business development initiatives Lipo Rejuvenation Centers, Cellular Treatment Programs, Laboratory Science Investigations, and its Skincare Brand, Stem Cellutrition.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Catherine Tung Harris, MD 2700 Clay Edwards Dr Ste 240, North Kansas City, MO 64116-3254 Ph: (816) 691-2021 | Catherine Tung Harris, MD 2700 Clay Edwards Dr Ste 240, North Kansas City, MO 64116-3254 Ph: (816) 691-2021 |
News Archive
Hyperion Therapeutics, Inc. announced today that its investigational compound glycerol phenylbutyrate (HPN-100) has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) as adjunctive therapy for the chronic management of urea cycle disorders. Hyperion recently completed its phase III trial which was conducted under a Special Protocol Assessment (SPA) agreement with the FDA. The Company plans to announce results from that trial later this year.
A team of researchers have found that the American workplace is a significant contributor to the obesity epidemic. In the review of shifts in the labor force since 1960 it was suggested that a sizable portion of the national weight gain can be explained by declining physical activity during the workday.
Patients with high cholesterol levels who continually take statins appear to have a lower risk of death over four to five years, regardless of whether they already have diagnosed heart disease, according to a report in the February 9 issue of Archives of Internal Medicine , one of the JAMA/Archives journals.
Advanced Cell Technology, Inc. has reported for the first time a robust and highly efficient process for the generation of high-purity hepatocytes (liver cells).
Stem Cell Assurance, Inc. announced today that the Company will be focusing on four business development initiatives Lipo Rejuvenation Centers, Cellular Treatment Programs, Laboratory Science Investigations, and its Skincare Brand, Stem Cellutrition.
› Verified 4 days ago
Dr. Richard Ainsworth Mills, M.D. Hospitalist Medicare: Medicare Enrolled Practice Location: 2790 Clay Edwards Dr Ste 520, North Kansas City, MO 64116 Phone: 816-221-6750 Fax: 816-221-2335 | |
Benjamin Saylor, DO Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2700 Clay Edwards Dr Ste 240, North Kansas City, MO 64116 Phone: 816-455-0681 Fax: 816-455-5294 | |
Srinivas R Bapoje, MD., MPH Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2790 Clay Edwards Dr, Suite 520, North Kansas City, MO 64116 Phone: 816-221-6750 Fax: 816-221-2335 | |
Parker William Redlien, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2700 Clay Edwards Dr Ste 240, North Kansas City, MO 64116 Phone: 816-455-0681 Fax: 816-455-5294 | |
Ian Richard Tally, D.O. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2700 Clay Edwards Dr Ste 240, North Kansas City, MO 64116 Phone: 816-455-0681 Fax: 816-455-5294 | |
Sandhya Thondapu Litterer, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2700 Clay Edwards Dr Ste 240, North Kansas City, MO 64116 Phone: 816-455-0681 Fax: 816-455-5294 |